[1]	H. Frangoul, D. Altshuler, M.D. Cappellini, Y. Chen, J. Domm, B.K. Eustace, et al.. CRISPR-Cas 9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med, 384 (3) ( 2021), pp. 252-260 DOI: 10.1056/nejmoa2031054

[2]

CRISPR Therapeutics. FDA accepts biologics license applications for exagamglogene autotemcel (exa-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia [Internet]. Boston: CRISPR Therapeutics; 2023 Jun 8 [cited 2023 Aug 10]. Available from: https://crisprtx.com/about-us/press-releases-and-presentations/fda-accepts-biologics-license-applications-for-exagamglogene-autotemcel-exa-cel-for-severe-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia.

[3]

CRISPR Therapeutics. CRISPR Therapeutics provides business update and reports first quarter 2023 financial results [Internet]. Boston: CRISPR Therapeutics; 2023 May 8 [cited 2023 Aug 10]. Available from: https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-provides-business-update-and-reports-first-quarter-2023-financial-results.

[4]	P. Weiss. CRISPR use in humans shows promise while experts weigh ethical concerns. Engineering, 6 (7) ( 2020), pp. 719-722

[5]	Ledford H, Callaway E.Pioneers of revolutionary CRISPR gene editing win chemistry Nobel [Internet]. London: Nature; 2020 Oct 7 [cited 2023 Aug 14] Available from: https://www.nature.com/articles/d41586-020-02765-9.

[6]	S.C.P. Williams. CRISPR narrows gap between genetically altered foods and consumers. Engineering, 20 ( 2023), pp. 6-8

[7]	Kansteiner F, Becker Z, Liu A, Sagonowsky E, Dunleavy K. Most expensive drugs in the US in 2023 [Internet]. Washington, DC: FiercePharma; 2023 May 22 [cited 2023 Aug 10]. Available from: https://www.fiercepharma.com/special-reports/priciest-drugs-2023.

[8]	Kingwell K.First CRISPR therapy seeks landmark approval [Internet]. London: Nature; 2023 Apr 03 [ cited 2023 Aug 10]. Available from: https://www.nature.com/articles/d41573-023-00050-8.

[9]	Ledford H.CRISPR gene therapy shows promise against blood diseases [Internet]. London: Nature; 2020 Dec 8 [ cited 2023 Aug 10]. Available from: https://www.nature.com/articles/d41586-020-03476-x#.

[10]

Locatelli F, Frangoul H, Corbacioglu S, de la Fuente J, Wall D, Capellini MD, et al. Efficacy and safety of a single dose of CTZ001 for transfusion dependent beta thalassemia and severe sickle cell disease [Internet]. Vienna: European Hematology Association Hybrid Congress; 2022 Jun 2 [ cited 2023 Aug 10]. Available from: https://library.ehaweb.org/eha/2022/eha2022-congress/366210.

[11]

Waldron J. Landmark approval for Vertex’s CRISPR drug 2 steps closer after trial wins, PDUFA date granted [Internet]. Washington, DC: FierceBiotech; 2023 Jun 9 [ cited 2023 Aug 10]. Available from: https://www.fiercebiotech.com/biotech/landmark-approval-vertexs-crispr-drug-two-steps-closer-after-trial-wins-pdufa-date-granted.

[12]

US Food and Drug Administration (FDA).FDA approves first cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who require regular blood transfusions [Internet]. Washington, DC: US Food and Drug Administration; 2022 Aug 17 [cited 2023 Aug 14]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-treat-adult-and-pediatric-patients-beta-thalassemia-who.

[13]

Bluebird Bio. Bluebird Bio announces FDA priority review of the biologics license application for lovotibeglogene autotemcel (lovo-cel) for patients with sickle cell disease (SCD) 12 years and older with a history of vaso-occlusive events [Internet]. Sommerville: Bluebird Bio; 2023 Jun 21 [ cited 2023 Aug 10]. Available from: https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-fda-priority-review-biologics-license-1.

[14]

Editas Medicine.Editas Medicine announces positive initial EDIT-301 safety and efficacy data from the first four patients treated in the RUBY trial and the first patient treated in the EdiTHAL trial [Internet]. Cambridge: Editas Medicine; 2023 Jun 9 [ cited 2023 Aug 10]. Available from: https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-positive-initial-edit-301-safety-and.

[15]

BEACON: a study evaluating the safety and efficacy of BEAM-101 in patients with severe sickle cell disease (BEACON) [Internet]. Washington,DC: US National Library of Medicine; 2023 May 19 [cited 2023 Aug 14]. Available from: https://clinicaltrials.gov/study/NCT05456880?term=Beam%20Therapeutics&intr=scd&rank=1.

[16]	E.B. Esrick, L.E. Lehmann, A. Biffi, M. Achebe, C. Brendel, M.F. Ciuculescu, et al.. Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. N Engl J Med, 384 (3) ( 2021), pp. 205-215 DOI: 10.1056/nejmoa2029392

[17]	Johnson C. A new era for treating sickle cell disease could spark a health-care revolution [Internet]. Washington, DC: The Washington Post; 2023 Apr 28 [ cited 2023 Aug 10]. Available from: https://www.washingtonpost.com/science/2023/04/28/sickle-cell-disease-treatment-gene-therapy/.

[18]	Mullard A.FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections [Internet]. London: Nature; 2023 Jun 23 [ cited 2023 Aug 10]. Available from: https://www.nature.com/articles/d41573-023-00103-y.

[19]

Beaudoin F, Thokala P, Nikitin D, Campbell J, Spackman E, McKenna A, et al. Gene therapies for sickle cell disease:effectiveness and value; draft evidence report [Internet]. Boston: Institute for Clinical and Economic Review; 2023 Apr 12 [cited 2023 Aug 10]. Available from: https://icer.org/wp-content/uploads/2023/04/SCD_FOR-PUBLICATION.pdf.

[20]	Molteni M. With CRISPR cures on horizon, sickle cell patients ask hard questions about who can access them [Internet]. Boston: Stat News; 2023 Mar 7 [cited 2023 Aug 10]. Available from: https://www.statnews.com/2023/03/07/crispr-sickle-cell-access/.

[21]	Iyer J. Sickle cell cures are coming. African children can’t be left behind [Internet]. Boston: Stat News; 2023 Jul 12 [cited 2023 Aug 10]. Available from: https://www.statnews.com/2023/07/12/sickle-cell-gene-therapy-cures-price-africa-access/.

[22]	Ledford H. “Astonishing” molecular syringe ferries proteins into human cells [Internet]. London: Nature; 2023 Mar 29 [ cited 2023 Aug 10]. Available from: https://www.nature.com/articles/d41586-023-00922-4.

[23]	J. Kreitz, M.J. Friedrich, A. Guru, B. Lash, M. Saito, R.K. Macrae, et al.. Programmable protein delivery with a bacterial contractile injection system. Nature, 616 (7956) ( 2023), pp. 357-364 DOI: 10.1038/s41586-023-05870-7